Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
BridgeBio Pharma Inc (BBIO)
NASDAQ:BBIO
BridgeBio Pharma (BBIO) Stock Price & Analysis
790 Followers
BBIO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$12.75 - $44.32
Previous Close$24.98
Volume1.72M
Average Volume (3M)1.70M
Market Cap
$4.61B
Enterprise Value$4.64B
Total Cash (Recent Filing)$434.88M
Total Debt (Recent Filing)$459.55M
Price to Earnings (P/E)-6.3
Beta1.33
Next Earnings
May 02, 2024EPS Estimate
-$0.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.95
Shares Outstanding175,831,536
10 Day Avg. Volume1,431,499
30 Day Avg. Volume1,700,892
Standard Deviation0.25
R-Squared0.05
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-3.28
Price to Sales (P/S)2543.26
Price to Cash Flow (P/CF)-9.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue499.14
Enterprise Value/Gross Profit677.20
Enterprise Value/Ebitda-11.56
Forecast
1Y Price Target
$50.73Price Target Upside103.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
BridgeBio Pharma News
Bulls Say, Bears Say
Bulls Say
Drug Development And Market PotentialAcoramidis shows positive trends on cardiac remodeling, indicating a strong potential in the treatment of ATTR-CM, which may lead to FDA approval and market growth.
Financial Performance And RatingsAnalyst indicates a 'Buy' rating with a high expected share price return for the company, reflecting confidence in the company's financial prospects.
Strategic PartnershipsBridgeBio's partnership with BAYRY for EU acoramidis rights could provide additional financial stability and growth opportunities, signaling investor confidence.
Bears Say
Competition And Market DynamicsPotential entry of Tafamidis generics by 2026 could significantly impact Acoramidis uptake.
Drug Efficacy And Market PerceptionAcoramidis met the primary endpoint in a CV outcomes trial without achieving statistically significant improvement in all-cause mortality, which was achieved by Tafamidis.
Financial PerformanceBBIO reported operating expenses above expectations, impacting the financial outlook.
---
Ownership Overview
50.37% Insiders
15.80% Mutual Funds
12.78% Other Institutional Investors
21.05% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BBIO FAQ
What was BridgeBio Pharma Inc’s price range in the past 12 months?
BridgeBio Pharma Inc lowest stock price was $12.75 and its highest was $44.32 in the past 12 months.
What is BridgeBio Pharma Inc’s market cap?
Currently, no data Available
When is BridgeBio Pharma Inc’s upcoming earnings report date?
BridgeBio Pharma Inc’s upcoming earnings report date is May 02, 2024 which is in 13 days.
How were BridgeBio Pharma Inc’s earnings last quarter?
BridgeBio Pharma Inc released its earnings results on Feb 22, 2024. The company reported -$0.96 earnings per share for the quarter, missing the consensus estimate of -$0.869 by -$0.091.
Is BridgeBio Pharma Inc overvalued?
According to Wall Street analysts BridgeBio Pharma Inc’s price is currently Undervalued.
Does BridgeBio Pharma Inc pay dividends?
BridgeBio Pharma Inc does not currently pay dividends.
What is BridgeBio Pharma Inc’s EPS estimate?
BridgeBio Pharma Inc’s EPS estimate is -$0.92.
How many shares outstanding does BridgeBio Pharma Inc have?
BridgeBio Pharma Inc has 184,452,220 shares outstanding.
What happened to BridgeBio Pharma Inc’s price movement after its last earnings report?
BridgeBio Pharma Inc reported an EPS of -$0.96 in its last earnings report, missing expectations of -$0.869. Following the earnings report the stock price went down -1.639%.
Which hedge fund is a major shareholder of BridgeBio Pharma Inc?
Among the largest hedge funds holding BridgeBio Pharma Inc’s share is Viking Global Investors LP. It holds BridgeBio Pharma Inc’s shares valued at 1B.
---
BridgeBio Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.73 (103.08% Upside)
$50.73 (103.08% Upside)
Blogger Sentiment
Bullish
BBIO Sentiment 85%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 822.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $44.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 20.0%
Last 30 Days ▲ 20.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
66.20%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.30%
Trailing 12-Months
Company Description
BridgeBio Pharma Inc
BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.
---
BBIO Stock 12 Months Forecast
Average Price Target
$50.73
▲(103.08% Upside)
Technical Analysis
Best Analysts Covering BBIO
1 Year
1 Year Success Rate
21/39 ratings generated profit
1 Year Average Return
+40.16%
reiterated a buy rating 29 days ago
Copying Salim Syed's trades and holding each position for 1 Year would result in 53.85% of your transactions generating a profit, with an average return of +40.16% per trade.
---